Table 2B.
Immune-related adverse events at least possibly related to study therapy.
| Event | Cohort Grade | A: P+B | B: P alone | A: P+B | B: P alone | A: P+B | B: P alone | A: P+B | B: P alone |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||||||
| Abdominal pain | 3 (6%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Alkaline phosphatase elevation | 2 (4%) | 1 (3%) | 0 | 0 | 0 | 0 | 0 | 0 | |
| ALT elevation | 7 (14%) | 1 (3%) | 0 | 0 | 1 (2%) | 0 | 0 | 0 | |
| AST elevation | 7 (14%) | 0 | 0 | 0 | 1 (2%) | 0 | 0 | 0 | |
| Arthralgia | 6 (12%) | 0 | 4 (8%) | 1 (3%) | 0 | 0 | 0 | 0 | |
| Bilirubin increase | 1 (2%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Cerebral edema | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (3%) | |
| Colitis | 0 | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Conjunctivitis | 1 (2%) | 1 (3%) | 0 | 0 | 0 | 0 | 0 | 0 | |
| Creatinine increase | 2 (4%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Diarrhea | 7 (14%) | 0 | 2 (4%) | 1 (3%) | 0 | 0 | 0 | 0 | |
| Dyspnea | 1 (2%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Hyperglycemia | 5 (10%) | 0 | 2 (4%) | 1 (3%) | 0 | 1 (3%) | 0 | 0 | |
| Hyperthyroidism | 4 (8%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Hypothyroidism | 3 (6%) | 1 (3%) | 2 (4%) | 1 (3%) | 0 | 0 | 0 | 0 | |
| Infusion reaction | 0 | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Myalgia | 6 (12%) | 0 | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
| Rash | 5 (10%) | 1 (3%) | 1 (2%) | 0 | 0 | 0 | 0 | 0 | |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; B, bevacizumab; P, pembrolizumab.